This uses cookies that do not gather any personal information whatsoever. By using this website, you agree with the cookie policy.
OK, I ACCEPT

 Pharmacogenomics

Organizer: Maria Manuela M. Grazina

Date: 23 - 27 March 2020



The course schedule can be found here




Background and Goals:

This course is directed to students aiming to understand the basic concepts and clinical applications of Pharmacogenomics.

The course will teach the basic principles of Biochemical Genetics underlying the variability in response to therapeutics, according to the genetic individual profile. Additionally, the most recent developments in pharmacogenomic approach to diseases and epigenetic effects of particular chemicals will be brought to discussion. The knowledge of the mechanisms involved in genetic and epigenetic modification, together with the identification of the genes codifying factors involved in drug response, is essential to understand the relevance of Pharmacogenomics in the development of new therapeutic agents and in the application of more rational therapies.

A “meet the expert” session is included to provide the students to interact with international expert scientists.

Paper club discussions are organized for achieving the most relevant and up-to-date findings in current literature and international guidelines.

Students are asked to suggest a guideline for the application of pharmacogenomic assays in the clinical practice, in an open discussion special session.



   

References:

Nogueira A, Catarino R, Faustino I, Nogueira‐Silva C, Figueiredo T, Lombo L, Hilário‐Silva I, Pereira D, Medeiros R.
Role of the RAD51 G172T polymorphism in the clinical outcome of cervical cancer patients under concomitant chemoradiotherapy. Gene. 2012 May 24.
de Mello RA, Marques DS, Medeiros R, Araújo AM. Epidermal growth factor receptor and K‐Ras in non‐small cell lung cancer‐molecular pathways involved and targeted therapies. World J Clin Oncol. 2011 10;2(11):367‐76.
Araújo AP, Ribeiro R, Pinto D, Pereira D, Sousa B, Mauricio J, Lopes C, Medeiros R. Epidermal growth factor genetic variation, breast cancer risk, and waiting time to onset of disease. DNA and cell biology 2009;28(5):265‐9.
Teixeira AL, Ribeiro R, Morais A, Lobo F, Fraga A, Pina F, Calais‐da‐Silva FM, Calais‐da‐Silva FE, Medeiros R.
Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. Pharmacogenomics J. 2009;9(5):341‐6.
Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El‐Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv. 2008;1(6):620‐7.
Gomez A, Ingelman‐Sundberg M. Epigenetic and microRNA‐dependent control of cytochrome P450 expression: a gap between DNA and protein. Pharmacogenomics. 2009;10(7):1067‐76.
Gupta M, Kaur H, Grover S, Kukreti R. Pharmacogenomics and treatment for dementia induced by Alzheimer's disease. Pharmacogenomics. 2008;9(7):895‐903.
Horstmann S, Binder EB. Pharmacogenomics of antidepressant drugs. Pharmacol Ther. 2009 Jun 27. [Epub ahead of print].
Jannetto PJ, Bratanow NC. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics. 2009;10(7):1157‐67.
Kim JH, Schwinn DA, Landau R. Pharmacogenomics and perioperative medicine‐‐implications for modern clinical
practice. Can J Anaesth. 2008;55(12):799‐806.
Ooteman W, Naassila M, Koeter MW, Verheul R, Schippers GM, Houchi H, Daoust M, van den Brink W.
Predicting the effect of naltrexone and acamprosate in alcohol‐dependent patients using genetic indicators. Addict Biol.
2009;14(3):328‐37.
Manolopoulos VG, Dechairo B, Huriez A, Kühn A, Llerena A, van Schaik RH, Yeo KT, Ragia G, Siest G.
Pharmacogenomics and personalized medicine in clinical practice. Pharmacogenomics. 2011;12(5):597‐610
Peñas‐Lledó EM, Blasco‐Fontecilla H, Dorado P, Vaquero‐Lorenzo C, Baca‐García E, Llerena A. CYP2D6 and the severity of suicide attempts. Pharmacogenomics. 2012;13(2):179‐84.
Peñas‐LLedó EM, Dorado P, Pacheco R, González I, LLerena A. Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers. Pharmacogenomics. 2009;10(7):1111‐20.
Other texts | outros textos.